01 — At a Glance
The Pharma Darling Goes MedTech. The Markets Yawned.
- 52-Week High / Low₹5,934 / ₹4,608
- Q3 FY26 Revenue₹3,737 Cr
- Q3 FY26 PAT₹653 Cr
- Q3 EPS (₹)53.19
- Annualised EPS (Q3×4)₹212.76
- Book Value₹1,116
- Price to Book4.95x
- Dividend Yield0.81%
- Debt / Equity0.18x
- Occlutech Deal₹1,100 Cr (~55%)
Auditor’s Note: Alkem just announced it’s acquiring 51–55% of Switzerland-based Occlutech (cardiac devices) for EUR 99.4 million (~₹1,100 crore). The pharma stock rallied sideways on this news because apparently, the market was already pricing in some diversification premium. P/E at 27.5x is nearly in line with peers. Revenue growth at 10.7% QoQ and 11.7% YTD. Meanwhile, ROCE sits at a respectable 20.4%, and they’re holding ₹4,081 crore in unencumbered cash. Everything screams “capital deployment time.” And they finally listened.
02 — Introduction
The Pharma Company That Suddenly Remembered: “Healthcare Is Bigger Than Pills”
Alkem Laboratories. Fifth-largest pharma company in India by market share (4.1%). A 1973-founded heavyweight in the business of making human beings slightly less sick through the miracle of tablets, capsules, and injectable solutions. Ranking #1 in anti-infectives. Top 3 in GI meds, pain killers, and vitamins. You know their brands even if you don’t know Alkem: CLAVAM, PAN, SUMO, Taxim-O. Your neighbourhood medical shop has a stack of them.
The stock has been a quiet compounding machine. Over the past three years, it’s delivered a 20% annualised return. Five years? 15%. Not flashy, not a 10x story, but steady cash-generating growth with a dividend payout of 37% and a management that doesn’t do stunts.
Then, on February 13, 2026, they announced something genuinely interesting: A binding offer to acquire up to 55% of Occlutech Holding AG — a Germany-headquartered, Switzerland-domiciled medical device company specialising in minimally invasive cardiac structural heart devices. Market cap of Occlutech: EUR 180.70 million. Alkem’s proposed cheque: EUR 99.4 million for 51–55% control. Expected close by June 2026.
The move signals Alkem is finally deploying its fortress balance sheet into something beyond incrementally optimising formulation margins. For a company sitting on ₹4,081 crore in liquid cash and generating ₹1,500+ crore in annual operating cash flow, the move makes mathematical sense. The question is: Does it make strategic sense? Let’s unpack the numbers, the logic, and whether the Indian investor market is ready for Alkem 2.0.
From the Feb 18, 2026 Investor Meet: Alkem MedTech CEO Kaustav Banerjee (30+ years in global medical devices, ex-VP South Asia at Zimmer, ex-MD at St. Jude Medical) walked through the vision: “Going deep and going wide” — structural heart as the anchor, ortho implants already scaling, and rest-of-world (ROW) expansion as the play. If this is your first MedTech rodeo, it’s either genius or expensive hubris. History will tell.
03 — Business Model: Pills + Implants = What Could Go Wrong?
They Make Drugs. Now They Want To Make Devices. Separately.
EduInvesting runs entirely on reader support — ₹360 a year keeps the lights on.
